Recorded Presentations from the NCCN 2023 Nursing Program: Advancing Oncology Nursing™
This program will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Presentations will focus on a current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.
This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.
The goal of the NCCN 2023 Nursing Program: Advancing Oncology Nursing™ is to ensure that oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to:
- Evaluate the advances in the management of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to Providing Access to Cancer Care in Historically Marginalized Communities: Lessons Learned from Dana-Farber’s Cancer Care Equity Program; Operational Excellence for Inpatient Rounding; Early Involvement of Palliative Care in Cancer Treatment; New Challenges in the Management of Pulmonary Toxicities; Management of Acute Hyperglycemia; Updates in Biomarker Testing in Non-Small Cell Lung Cancer; and Harm Reduction Strategies for Substance Use in Patients with Cancer.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Christopher Acebedo, DNP, MS, RN, ACNP-BC
Jessica Cerulli, DNP, FNP-C, RN
Rachael Fornwalt, AG-ACNP
Kristina M. Gregory, RN, MSN, OCN
Carey Ramirez, ANP-C, ACHPN
Ludmila Svoboda, RN, BSN, MA, OCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Gretchen McNally, PhD, ANP-BC, AOCNP
JADPRO Insight Forum: Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support
Zoe Quandt, MD
Novartis Pharmaceuticals Corporation: Scientific Advisor
Beth Sandy, MSN, CRNP
Amgen Inc.: Product/Speakers Bureau
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Eli Lilly and Company: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
Takeda Pharmaceuticals North America, Inc.: Product/Speakers Bureau
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
These activities are approved for nursing contact hours. Complete accreditation information is provided before each individual educational activity.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing